Articoli: 162

Tom Hayes

Journalist and Social Media Manager

Tom Hayes is a journalist, social media manager and patient advocate specialising in the fields of HIV and Sexual Health. Working in HIV since 2011 Tom is a trustee of the Saving Lives charity, and BHIVA representative.

Tutte le notizie / Autore Tom Hayes

14 giugno 2022

2297

First data from the Trimer 4571 HIV vaccine trial on humans

Specialists from the Clinical Centre of the National Institute in Maryland, USA, have revealed the preliminary results from a Phase I clinical trial of the Trimer 4571 HIV vaccine which uses aluminium hydroxide as an adjuvant. Antibodies binding Trimer 4571 were found ...

20 maggio 2022

2095

Georgia is the latest US state to update its laws around HIV transmission

The Governor of Georgia has signed a bill to modernise the state’s laws related to HIV transmission. Previously, a person living with HIV could have faced a felony charge and up to 10 years in prison for not disclosing their HIV status before ‘any type of sexual act’ ...

29 aprile 2022

3235

Basketball legend Magic Johnson speaks about how be “became the face of HIV”

Magic Johnson, a name synonymous with both basketball and HIV activism. He proved that HIV doesn’t have to be a barrier to both a personal life or a career. Magic Johnson has been living openly with HIV for 30 years, achieved great success in the world of sports, and ...

29 aprile 2022

2136

Johnson & Johnson sues to prevent “fake” HIV drugs being distributed

US pharmaceutical giant Johnson & Johnson has sued pharmacies and drug distribution firms to stop them selling “fake” versions of its HIV drugs, reports Reuters. This case follows similar action from Gilead Sciences. Johnson & Johnson representatives reported that they ...

29 aprile 2022

2109

Lost to follow-up: An analysis of people in South London who dropped out of HIV care

According to the UK Health Security Agency, the number of people who dropped out of HIV care may have doubled during the COVID-19 pandemic. Dr Kate Childs of King’s College London and her colleagues at St Thomas’ and Lewisham Hospitals conducted set up a study to investigate ...

29 aprile 2022

2747

Theratechnologies pulls of out Europe, taking ibalizumab with it

Biotech company Theratechnologies, which develops innovative therapies, has announced that it is withdrawing from the European market and will now focus its activities solely in North America. Accordingly, the company will be ceasing the sale of their monoclonal antibody ...

25 marzo 2022

2193

Men living with HIV twice as likely to experience certain cancers

Researchers from Cleveland, Ohio, found that men living with HIV were almost twice as likely to also have cancer when compared to men who are HIV negative. The risk of developing a tumour also appears to increase significantly in the presence of high viral load. The analysis ...

21 marzo 2022

2822

Moderna announces first trial participants have received the Trimer mRNA HIV vaccine

Moderna, a biotechnology and pharmaceutical company based in Massachusetts, have announced the launch of Phase I of clinical trials into their Trimer mRNA HIV vaccine (mRNA-1574). The first participants has now received their first dose of the mRNA-based vaccine. The ...

21 marzo 2022

2426

For Life4me+ 2021 was all about “Respect my HIV”

For Life4me+, 2021 was a very busy year. Despite the fact that everyone had to learn to live in the reality of COVID-19, it was a year of scientific success in the field of HIV - after the stagnation of 2020. 2021 was a year of new information projects and conferences ...

14 marzo 2022

2448

‘Dare to share care’ campaign launched to support HIV care in Ukraine

Europe is home to almost three million people living with HIV, with over 250,000 of those living in Ukraine. The invasion of Ukraine and the armed conflict have threatened the care for those quarter of a million people. The Young Investigators (YING) in partnership with ...